Chris Martin, ADC Therapeutics CEO

ADC Ther­a­peu­tics nabs its first ap­proval as FDA of­fers a quick OK for its DL­B­CL can­cer treat­ment

The FDA won’t be wait­ing around for the PDU­FA date for its lat­est OK on the can­cer front.

Reg­u­la­tors came through with an ac­cel­er­at­ed ap­proval for ADC Ther­a­peu­tics’ lon­cas­tux­imab tesirine-lpyl as a third-line ther­a­py for dif­fuse large B-cell lym­phoma, which was ba­si­cal­ly a shoe-in look­ing for an OK in drug re­sis­tant pa­tients with a pri­or­i­ty re­view at­tached to the ap­pli­ca­tion.

This CD-19 an­ti­body drug con­ju­gate will now be sold as Zyn­lon­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.